Takeda Oncology Here2Assist™


 Takeda Oncology Here2Assist:

  • Works with your patients' insurance company to help get your patients started on their medication
  • Identifies available financial assistance that may be right for your patients
  • May help eligible patients get started on treatment in the event of an insurance delay
  • Identifies specialty pharmacies to help fill and ship your patients' prescriptions appropriately
  • Conducts regular follow-up calls to patients
  • Sends text message status updates and reminders to patients*
  • ACCESS SUPPORT: Takeda Oncology Here2Assist case managers can work with your patients to determine their coverage options and provide additional support to patients throughout their treatment
  • FINANCIAL ASSISTANCE: Takeda Oncology Here2Assist case managers can help identify financial assistance programs that may be able to help your patients with the cost of their treatment
  • HELPFUL RESOURCES: Takeda Oncology Here2Assist case managers can provide your patients with information about additional resources that may assist with the day-to-day support they need

For more information about access support and financial assistance that your patients may qualify for, visit www.Here2Assist.com/hcp or call us at 1‑844‑817‑6468, Option 2.

Lets Talk. We’re available Monday-Friday, 8AM-8PM ET.

*Patients will need to enroll in the texting program to receive text messages.


 

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib) and entering one that is not owned or controlled by Takeda Oncology.

Takeda Oncology makes no representation as to the accuracy of the information contained on sites we do not own or control. Takeda Oncology does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Cancel Continue +

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib) and entering one that is not owned or controlled by Takeda Oncology.

This link will take you to the corporate ARIAD Pharmaceuticals, Inc. website.

Cancel Continue
Close

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib).

This link will take you to another Takeda Oncology website.

Cancel Continue +

The site you are about to enter is intended for US healthcare professionals only.

Please confirm that you are a US healthcare professional.

Yes, I confirm that I am a US healthcare professional Cancel +

In Vitro: ALUNBRIG Inhibited 17
ALK-Inhibitor—Resistant Mutations1,2

ALUNBRIG exhibited in vivo antitumor activity against 4 mutant forms of EML4-ALK, including the G1202R and L1196M mutants identified in NSCLC tumors in patients who had progressed on crizotinib.